In response to emergent resistance to other artemisinin-based combination therapies, dihydroartemisinin- piperaquine became the drug of choice to treat artemisinin-resistant Plasmodium falciparum in Southeast Asia and is being used in large scale targeted mass treatment field evaluations to eliminate malaria in the region in hopes of preventing the spread of drug resistance. However, the emergence of piperaquine resistance is compromising the last effective antimalarial for Southeast Asia, which bodes poorly for the ability to treat this important disease in this part of the world. Identification of molecular markers for use in surveillance would provide a rapid means to measure the present extent of piperaquine resistance and guide rational containment strategies to deter its further spread. We have conducted a genome-wide association study that has identified multiple regions of the parasite genome that are significantly associated with ex vivo piperaquine susceptibility. We propose to identify specific genes and polymorphisms within these regions of the P. falciparum genome and to validate these candidate resistance markers in the field and in the laboratory. The work will be accomplished in three aims. First, we will identify candidate piperaquine resistance genes and polymorphisms using an annotated reference P. falciparum genome assembly for Southeast Asia. Candidate resistance genes will be identified and prioritized, and whole genome sequencing will be used to identify single nucleotide polymorphisms within candidate genes or gene copy number variants and their association with ex vivo piperaquine susceptibility. Rapid assays will be developed to genotype candidate resistance markers significantly associated with the phenotype. Second, we will use the rapid assays developed as part of Aim 1 to genotype candidate piperaquine resistance markers in P. falciparum infections collected as part of dihydroartemisinin-piperaquine efficacy studies, and we will estimate the association between candidate resistance markers and clinical outcomes following treatment with dihydroartemisinin-piperaquine. Third, we will use CRISPR/Cas9-mediated gene editing to introduce candidate resistance mutations identified in Aims 1 and 2 into piperaquine-sensitive parasite isolates and to remove candidate resistance mutations from piperaquine-resistant parasite isolates to validate the role of these mutations in determining susceptibility to piperaquine. If successful, this project will result in a greater understanding of the molecular mechanisms underlying piperaquine resistance, as well as genetic markers that can be used to track and contain piperaquine-resistant parasites and guide malaria drug treatment policies.

Public Health Relevance

Dihydroartemisnin-piperaquine, the drug of choice to treat malaria resistant to other artemisinin-based combination therapies, is threatened by the recent emergence of piperaquine-resistant malaria parasites. Since malaria-endemic countries in Southeast Asia plagued by artemisinin resistance rely on this drug to treat malaria, the spread of piperaquine-resistant parasites could result in the inability to successfully treat this devastating disease in this part of the world. This project aims to identify parasite genes and mutations underlying piperaquine resistance, in an effort to develop tools to track resistant parasites and contain them before they spread.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI125579-02
Application #
9422668
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Joy, Deirdre A
Project Start
2017-02-03
Project End
2022-01-31
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
2
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201